Popular Filters
Trials for AD Patients
Janus Kinase (JAK) Inhibitor
Ruxolitinib Cream for Atopic Dermatitis/Eczema
This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.
Monoclonal Antibodies
Eblasakimab for Eczema
This trial is testing a new medication called eblasakimab for people with moderate-to-severe atopic dermatitis who have already tried another treatment called dupilumab. The medication aims to reduce skin inflammation and improve symptoms. The study will last for several months, including a treatment period and a follow-up.
Trials for Eczema Patients
Monoclonal Antibodies
Nemolizumab for Eczema
This trial is testing nemolizumab, a medication designed to help children with moderate-to-severe eczema. Nemolizumab is a medication developed for treating skin diseases, including severe eczema. The drug works by blocking proteins that cause skin problems and itching. Researchers aim to see how well it works and if it is safe for these children.
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Monoclonal Antibodies
Dupilumab for Eczema
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
Trials With No Placebo
Janus Kinase (JAK) Inhibitor
Ruxolitinib Cream for Atopic Dermatitis/Eczema
This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.
View More Related Trials
Frequently Asked Questions
Introduction to atopic dermatitis
What are the top hospitals conducting atopic dermatitis research?
When it comes to advancing the treatment options for atopic dermatitis, several hospitals are leading the way. In sunny Los Angeles, Dermatology Research Associates takes the spotlight with an impressive 14 active clinical trials dedicated to atopic dermatitis. With a track record of 29 completed studies since their first trial in 2005, this institution is committed to finding innovative solutions for this chronic skin condition. Meanwhile, First OC Dermatology in Fountain Valley has emerged as a significant player in recent years, currently conducting 11 active trials and boasting a total of 30 completed studies since starting their research on atopic dermatitis in 2018.
Heading eastward to Indianapolis, Dawes Fretzin Clinical Research Group LLC is making substantial contributions with nine ongoing clinical trials focused on atopic dermatitis. Since initiating their first trial back in 2005, they have conducted a commendable number of 26 studies aimed at understanding and managing this condition effectively.
On the scenic coast of Santa Monica lies the Clinical Science Institute which currently oversees eight active clinical trials for atopic dermatitis while having achieved notable success through twenty-four previous investigations that date back to their inaugural study launched just five years ago in2016.Finally,Poised amidst San Antonio's vibrant medical community,is Progressive Clinical Research where seven current ventures center around studying Atopiic Dermatitis; These derive from twenty-seven such conducted projects,together contributing towards promoting better routes forward beginning only four years ago during2017
These hospitals represent beacons of hope and progress within the field of atopic dermatitis research. Through these collective efforts and countless others like them across the globe we can strive towards improving quality of life for individuals affected by this challenging skin condition
Which are the best cities for atopic dermatitis clinical trials?
When it comes to atopic dermatitis clinical trials, several cities stand out as hubs for research and development. Miami, Florida leads the way with 78 active trials exploring treatments like Lebrikizumab, Nemolizumab, and etrasimod. Los Angeles, California closely follows with 53 ongoing studies focused on medications such as Lebrikizumab, Upadacitinib, and Nemolizumab. Tampa, Florida also shows promise with 52 active trials investigating therapies like Nemolizumab and Lebrikizumab. Additionally, New york City boasts 39 ongoing trials studying medications including Lebrikizumab and Nemolizumab. Finally, San Antonio, Texas demonstrates its commitment to advancing care through its involvement in 37 active trials examining treatments like Lebrikizumab and ASN008 5%. These cities offer individuals suffering from atopic dermatitis access to cutting-edge clinical trials that hold potential for improved management of this condition.
Which are the top treatments for atopic dermatitis being explored in clinical trials?
Atopic dermatitis, a challenging skin condition, is currently the focus of several exciting treatments being investigated in clinical trials. Leading the way is dupilumab, with 5 active trials and an impressive track record of 39 all-time atopic dermatitis studies since its initial listing in 2011. closely following are upadacitinib and nemolizumab, both involved in five ongoing trials and showing promise for patients. Joining them is lebrikizumab, engaged in four current studies to explore its effectiveness. Lastly, rocatinlimab holds potential as well with three active trials dedicated to evaluating its impact on atopic dermatitis symptoms. These innovative therapies bring hope for improving the lives of those affected by this chronic skin condition.
What are the most recent clinical trials for atopic dermatitis?
Recent advancements in clinical trials for atopic dermatitis offer hope for improved management of this chronic skin condition. One such trial is evaluating the efficacy of Stage 1_PF-07275315, a potential treatment that has entered Phase 2 and became available on August 22, 2023. Additionally, another promising candidate is IMG-007 Dose 1, which has progressed to both Phase 1 and Phase 2 stages since becoming available on August 9, 2023. Furthermore, Dupilumab's Phase 4 trial aims to expand our knowledge about its effectiveness in treating atopic dermatitis after being made available on August 1, 2023. These studies highlight the ongoing commitment to finding effective therapies that can alleviate symptoms and improve quality of life for individuals with atopic dermatitis
What atopic dermatitis clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of atopic dermatitis, offering hope for improved treatments. Notably, in January 2022, Evelo Biosciences completed a trial investigating EDP1815's effectiveness. Around the same time, Regeneron Pharmaceuticals concluded their study on dupilumab and LEO Pharma wrapped up testing tralokinumab. These breakthroughs were preceded by promising trials such as Incyte Corporation's investigation into ruxolitinib cream (completed in December 2021) and Dermavant Sciences' exploration of tapinarof cream (completed multiple times between September and November 2021). Other noteworthy advancements include Bristol-Myers Squibb's research on Branebrutinib (completed in August 2021) and Arcutis Biotherapeutics' investigation into ARQ-151 Active (concluded in April 2021). These recent achievements underscore the commitment of researchers to finding effective solutions for atopic dermatitis patients.